gesunheitpfleges.org



Agilent launches SureCycler 8800 thermal cycler

March 11, 2016

Patients with schizophrenia who are non-adherent to medication are almost five times more likely to relapse than those patients who are adherent, significantly increasing the likelihood of relapse and hospitalisation, which in turn increases the overall cost of care. Frequent relapses and hospitalisation can increase a person's isolation and make it even more difficult for them to find and keep a job.

"Regular periods of hospitalisation following an acute episode is extremely damaging for patients with schizophrenia and their families and friends," said Dr Lupe Martinez, Medical Affairs Director, Janssen EMEA. "Not only does it place a significant strain on families, but it can damage friendships and make it extremely difficult for someone with schizophrenia to be self-sufficient and stay in employment. This data supports the important role of antipsychotic medication to help keep a person's symptoms under control and keep their lives stabilised."

Risperdal? Consta? was the first long-acting injectable second-generation antipsychotic to be licensed for the maintenance treatment of schizophrenia in patients currently stabilised with oral antipsychotics. It has been shown to reduce the risk of relapse and re-hospitalisation and is associated with a reduction in overall treatment costs per patient compared to other antipsychotics.  Reducing the rate of hospitalisation in patients with schizophrenia is a key public health priority, given the significant burden of this illness on healthcare systems, patients and their family and friends.

SOURCE Janssen Pharmaceutical Companies